Efficacy of Early Intravenous High-dose Vitamin C in Post-cardiac Arrest Shock.
A legfontosabb adatok
- Ki végzi
- Centre Hospitalier de Bethune
- Hol
- Franciaország14 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Leállítva
- Fázis
- 2. fázis
- Résztvevők
- 65 fő vett részt
- Kezdés
- 2023. dec. 27.
- Befejezés
- 2026. szept. 30.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
- A vizsgált kezelések
- Vitamin C (Laroscorbine) + Vitamin B1 (Bevitine)
- standard treatment
- A regiszteradat frissítve
- 2026. október 27.
- Miért állt le
- following new data on vitamin C and at the request of the ANSM
Ki vehet részt
- Életkor
- 18 év felett
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 16 feltétel megnézéseKevesebb
Ki vehet részt
- patients still comatose (Glasgow coma scale < 8) after an OHCA of presumed cardiac origin with ROSC < 60 min
- and treated with a norepinephrin or an epinephrin continuous infusion during at least 30 min before randomization to maintain mean arterial pressure (MAP) ≥ 65 mmHg
Ki nem vehet részt
- and treated with a norepinephrin or an epinephrin continuous infusion ≥ 0.2µg/kg/h, within 4 hours after OHCA, during at least 30 min/h to maintain mean arterial pressure (MAP) ≥ 65 mmHg
- patients already treated with vit-C; known vit-C deficit
- patients still comatose (Glasgow coma scale < 8) after an OHCA of presumed cardiac origin with ROSC < 60 min
- OHCA from evident extracardiac cause (trauma, bleeding, poisoning, etc.)
- history of urolithiasis, oxalate nephropathy or hemochromatosis
- pre-existent severe chronic kidney disease (glomerular filtration rate < 30ml/min)
- glucose-6-phosphate deshydrogenase deficiency; nephrolithiasis, hyperoxalyurie
- minor or pregnant women
- interval between RACS and randomization > 6 hours
- extracorporeal circulatory assistance requirement in the first 4 hours after OHCA
- inclusion in another study
- treatment limitationsor moribound
- Patient with derpived freedom or with legal protective measures
- Patient not covered by French national health insurance
Hol van ez a vizsgálat?
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
Among patients admitted after an out-of-hospital cardiac arrest (OHCA) in intensive care unit (ICU), almost two thirds of patients will develop in the first hours a post-cardiac arrest (CA) shock. This post-CA shock, combines cardiac and hemodynamic failure, generally resulting in multi-organ failure and early death in up to 35% of patients. Experimental data suggest that intravenous ascorbic acid (vitamin C) may attenuate inflammation and vascular injury related to sepsis or surgery. Preclinical and clinical studies also provide safety data of high dose intravenous vitamin C (> 200mg/kg/day) with no significant adverse event reported and favorable impact on outcome. Experimental data also suggest beneficial effect of vitamin C in post-CA management with improvement of shock and multi-organ failure with potential benefit on neuroprotection and outcome.
A teljes eredeti leírásKevesebb
The study is a phase II multicenter prospective controlled open-label trial randomized in two parallel groups :
* Expérimental group: Standard of care care for post-CA shock + Vitamin C (Vit-C) 200mg/kg/d IV (started as early as possible, no later than 1 h after randomization + thiamin (Vit B1) 200mg every 12 h during 3 days. * Control group: Standard of care care for post CA shock according international guidelines.
Patient number to be enrolled : 234, Study duration :24 months and 28 days, Inclusion duration : 24 months, Patient participation : duration : 28 days
A vizsgálat 2 csoportja
- Control groupMár használt kezelés, összehasonlításként
\- Control group (standard treatment): post-cardiac arrest care will be provided, including temperature control, according to current international guidelines and local procedures. Standard IV vit-C supplementation will be allowed for dosages up to 1000 mg a day from day 4 after randomization, as well as thiamin supplementation.
Kezelés: standard treatment
- Experimental groupA vizsgált kezelés
\- Experimental group (IV high-dose vit-C): in addition of standard post-CA as the control group, patients will receive an IV high-dose vit-C 50mg/kg infusion every 6 hours, started within the hour after randomization, for 3 days. In addition, all patients will receive intravenous thiamine 200 mg twice a day for 3 days to limit the oxalate production.
Kezelés: Vitamin C (Laroscorbine) + Vitamin B1 (Bevitine)
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Efficacy of Early Intravenous High-dose Vitamin C in Post-cardiac Arrest Shock: a Multicenter, Randomized Controled Trial.
- Publikációk
- A regiszteradat frissítve
- 2026. október 27.